Another factor in our favor, all interest parties can clearly see how much ACAD is paying in milestones and royalties. When they add those monies across 3 further indications that are shovel ready for ph3 and possibly 6 not yet announced Ph2 trials which we can afford to run. It’s not that hard to put a DCF valuation on the company.
It’s got to be a knockout offer according to Gerry. That webinar was a direct sales pitch. What we’ve got, how we can afford to go alone , how valuable the uplift will be. And how they are budging unless it’s a “ knockout offer”x
Which the BOD will need to put to the shareholders if a formal offer is presented. Even if they don’t accept the SP will appreciate very fast payments to that level!
NEU Price at posting:
$12.28 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)